B
Bernard Chevalier
Researcher at Saarland University
Publications - 258
Citations - 11496
Bernard Chevalier is an academic researcher from Saarland University. The author has contributed to research in topics: Stent & Percutaneous coronary intervention. The author has an hindex of 50, co-authored 240 publications receiving 10009 citations. Previous affiliations of Bernard Chevalier include University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial
Patrick W. Serruys,Bernard Chevalier,Dariusz Dudek,Angel Cequier,Didier Carrié,Andrés Iñiguez,Marcello Dominici,René J van der Schaaf,Michael Haude,Luc Wasungu,Susan Veldhof,Lei Peng,Peter Staehr,Maik J. Grundeken,Yuki Ishibashi,Hector M. Garcia-Garcia,Yoshinobu Onuma +16 more
TL;DR: Primary clinical and procedural outcomes after 1 year of follow-up are vasomotion and difference between minimum lumen diameter after nitrate administration after the index procedure and at 3 years and composite clinical endpoints based on death, myocardial infarction, and coronary revascularisation are reported.
Journal ArticleDOI
Transfemoral aortic valve implantation new criteria to predict vascular complications.
Kentaro Hayashida,Thierry Lefèvre,Bernard Chevalier,Thomas Hovasse,Mauro Romano,Philippe Garot,Darren Mylotte,Jhonathan Uribe,Arnaud Farge,Patrick Donzeau-Gouge,Erik Bouvier,B. Cormier,Marie-Claude Morice +12 more
TL;DR: Routine application of SFAR will improve patient selection for transfemoral TAVI and may improve outcome, and VARC major vascular complications increase 30-day mortality and are predicted by experience, femoral calcification, and SFAR.
Journal ArticleDOI
Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes
Patrick W. Serruys,Yoshinobu Onuma,Dariusz Dudek,Pieter C. Smits,Jacques J. Koolen,Bernard Chevalier,Bernard De Bruyne,Leif Thuesen,Dougal McClean,Robert-Jan van Geuns,Stephan Windecker,Robert Whitbourn,Ian T Meredith,Cecile Dorange,Susan Veldhof,Karine Miquel Hebert,Krishnankutty Sudhir,Hector M. Garcia-Garcia,John A. Ormiston +18 more
TL;DR: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss as mentioned in this paper.
Journal ArticleDOI
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
Patrick W. Serruys,Bernard Chevalier,Yohei Sotomi,Angel Cequier,Didier Carrié,Jan J. Piek,Ad J. van Boven,Marcello Dominici,Dariusz Dudek,Dougal McClean,Steffen Helqvist,Michael Haude,Sebastian Reith,Manuel de Sousa Almeida,Gianluca Campo,Andrés Iñiguez,Manel Sabaté,Stephan Windecker,Yoshinobu Onuma +18 more
TL;DR: The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel and a higher rate of device-oriented composite endpoint due to target vessel myocardial infarction.
Journal ArticleDOI
Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery StenosisClinical Perspective
Patrick W. Serruys,Yoshinobu Onuma,John A. Ormiston,Bernard De Bruyne,Evelyn Regar,Dariusz Dudek,Leif Thuesen,Pieter C. Smits,Bernard Chevalier,Dougal McClean,Jacques J. Koolen,Stephan Windecker,Robert Whitbourn,Ian T. Meredith,Cecile Dorange,Susan Veldhof,Karine Miquel-Hebert,Richard Rapoza,Hector M. Garcia-Garcia +18 more
TL;DR: Modified manufacturing process of the polymer and geometric changes in the polymeric platform have substantially improved the medium-term performance of this new generation of drug-eluting scaffold to become comparable to those of current drug eluting stents.